See the DrugPatentWatch profile for cosentyx

Based on the information provided, I was unable to find specific data or studies comparing the immune response to inactivated vaccines when taken with Cosentyx (secukinumab) versus without it. However, I can provide some general context that might be helpful.

Cosentyx is a monoclonal antibody used to treat various inflammatory diseases, such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It works by inhibiting interleukin-17A (IL-17A), a cytokine involved in the immune response [1].

Inactivated vaccines, on the other hand, contain killed or altered pathogens and are designed to stimulate a protective immune response without causing the disease [2]. Since Cosentyx affects the immune system, it is essential to consider its potential impact on vaccine efficacy.

According to DrugPatentWatch.com, there are ongoing clinical trials investigating the safety and immunogenicity of various vaccines in patients receiving biologic therapies, including Cosentyx [3]. However, the results of these studies are not yet available.

In summary, while there is no direct evidence comparing vaccine immunity with and without Cosentyx, it is crucial to consider the potential impact of biologic therapies on vaccine efficacy. Patients should consult their healthcare providers for personalized advice on vaccinations while taking Cosentyx.

Sources:
[1] Novartis. (2021). Cosentyx (secukinumab). <https://www.novartis.com/our-work/therapeutic-areas/immuno-dermatology/cosentyx>
[2] World Health Organization. (2018). Inactivated vaccines. <https://www.who.int/news-room/q-a-detail/inactivated-vaccines>
[3] DrugPatentWatch.com. (2022). Secukinumab (Cosentyx) Clinical Trials. <https://www.drugpatentwatch.com/drugs/secukinumab>